Form D · Biotechnology
Pandion Therapeutics Holdco LLC
Cambridge, MA · CIK 0001807901
Offering snapshot reported Apr 7, 2020 · SEC filing
- Reported sold
- $40M Offering amount: $80M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 23, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 7, 2020 | Initial | $39,999,997 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-364484
Source: Form D, filed Apr 7, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Becker | Director |
| Jill Carroll | Director |
| Alan L. Crane | Director |
| Donald Frail | Director |
| Christopher Fuglesang | Director |
| Vikas Goyal | Executive |
| Rahul Kakkar | Director, Executive |
| Mitchell Mutz | Director |
| Carlo Rizzuto | Director |
| Nancy Stagliano | Director |
| Jo Viney | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
610 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139